LLY Eli Lilly and Company
Company Analysis
Latest News
Lilly's Next-Gen Drug Crushes Ozempic in Head-to-Head Trial — But Can It Justify a Trillion-Dollar Valuation?
Shares of Eli Lilly surged +4.4% to $1,344.79 after the company reported that its experimental injectable, retatrutide, demolished Novo Nordisk's Ozempic in...
🟢 Eli Lilly is trading 8% up today after raising 2026 revenue outlook
Eli Lilly is trading at $1392.02, up 8.05%, after strong demand for Mounjaro and Zepbound drove third-quarter results. - On October 29, 2026, Eli Lilly...
Eli Lilly's third quarter 2026 revenue of $24.4B beat estimates behind surging tirzepatide demand
Eli Lilly reported a significant top- and bottom-line beat for the third quarter 2026, driven by a 53% increase in total volume primarily from its obesity and...
🟢 Eli Lilly is trading 4.38% up in pre-market after retatrutide beats Ozempic in Phase 3 trial
Eli Lilly is trading at $1,344.79, up 4.38%, after Eli Lilly reported Wednesday that its investigational retatrutide outperformed Ozempic on blood-sugar...
Eli Lilly Reports Retatrutide Beat Ozempic on Blood Sugar and Weight
Eli Lilly announced positive topline results from its TRANSCEND-T2D-2 Phase 3 trial of experimental drug retatrutide. In a head-to-head study of adults with...
Eli Lilly and Company Q3 2026 Earnings Preview: What Analysts Expect on October 29, 2026
Eli Lilly is expected to report Q3 2026 revenue of $22.58 billion and an EPS of $5.38, while the current stock price of $1,273.46 remains below the $1,343.50...
Healthcare Stocks Surge as AI Spending Concerns Spur Defensive Shift
Investors are moving capital out of high-flying artificial intelligence and technology stocks and into defensive sectors, with healthcare emerging as a major...
Eli Lilly Keeps Zepbound Ads After Judge Rejects Novo Nordisk Bid
A U.S. district judge on Monday denied Novo Nordisk's request to block rival Eli Lilly from advertising its weight-loss drugs. Lilly can continue its current...
🔴 Eli Lilly is trading 3.13% down amid broader market pressure
Eli Lilly is trading 3.13% down at $1,265.80, amid pressure on healthcare shares and broader risk-off sentiment; no clear company-specific negative...
🟢 Eli Lilly is trading 3.27% up today after groundbreaking at a $5 billion Virginia facility
Eli Lilly is trading 3.27% up at $1,312.29 after coverage linked the rise to its October 22, 2026, groundbreaking on a $5 billion manufacturing facility in...
Eli Lilly and Mubadala Bio Announce Strategic Collaboration for GLP-1 Medicines in Abu Dhabi
Eli Lilly and Company collaborates with Mubadala Bio. This partnership advances localized packaging and logistics for Lilly's GLP-1 medicines in Abu Dhabi. The...
🟢 Eli Lilly is trading 4.35% up on October 20, 2026, amid healthcare gains; catalyst unconfirmed
Eli Lilly is trading 4.35% higher at $1,294.30, supported by healthcare strength; no single catalyst is confirmed. - Healthcare rose 2.12% during the regular...
Eli Lilly Strikes Up-to-$1.1 Billion Drug Delivery Deal With Metis TechBio
Eli Lilly and Company has entered a strategic collaboration with Hong Kong-listed Metis TechBio to develop tissue-specific drug delivery technologies. The...
🟢 Eli Lilly is trading 3.98% up today as investors rotate into defensive healthcare stocks
Eli Lilly is trading 3.98% up at $1,256.84 as defensive healthcare-sector demand supports the move. - Investors rotated into defensive healthcare stocks after...
🟢 Eli Lilly is trading 3.45% up on October 14, 2026, amid a healthcare sector rally
Eli Lilly is trading at $1,206.78, up 3.45%, alongside a healthcare sector gain of 1.64% in the regular session; no direct link has been established. -...
Eli Lilly's Oral Obesity Drug Foundayo Sees Weekly Prescriptions Dip
IQVIA data shows a downturn in weekly U.S. prescriptions for new oral obesity drugs from Eli Lilly and Novo Nordisk. Prescriptions for Lilly's Foundayo fell...
🔴 Eli Lilly is trading 3.39% down on October 8, 2026, amid oil-supply and rate concerns
Eli Lilly is trading at $1,148.38, down 3.39%, amid broad risk-off pressure; no clear company-specific catalyst has been identified. - Attacks in Saudi Arabia...
🟢 Eli Lilly is trading 3.02% up today as healthcare gains on defensive demand
Eli Lilly is trading 3.02% up at $1,192.45, outperforming a weaker broader market as healthcare stocks draw defensive buying. - Healthcare is up 1.25%, with...
Eli Lilly and insitro Make AI Drug Discovery Models Available to Biotech Companies
Eli Lilly and Company partnered with AI firm insitro. They announced advanced machine learning models are now accessible to select biotech companies. These...
Eli Lilly Expands Drug Discovery Pact with Gate Bioscience for Over $870 Million
Eli Lilly expanded its research and licensing agreement with Gate Bioscience. The expansion adds over $870 million in potential value to their existing...